{
  "name": "Substance/Medication-Induced Psychotic Disorder",
  "slug": "substance-medication-induced-psychotic-disorder",
  "type": "condition",
  "metadata": {
    "category": "psychotic-disorders",
    "dsm5_code": "292.9",
    "icd10_code": "F1x.5x (varies by substance)"
  },
  "content": {
    "description": "Prominent hallucinations and/or delusions that are judged to be the direct physiological effect of a substance (drug of abuse, medication, toxin) and arise during or soon after intoxication, withdrawal, or exposure. The disturbance is not better explained by a primary psychotic disorder and does not occur exclusively during delirium.",
    "diagnostic_criteria": "A. Presence of delusions and/or hallucinations. B. Evidence from history, exam, or labs that symptoms developed during/soon after substance intoxication, withdrawal, or exposure to a medication and the substance is capable of producing such symptoms. C. Not better explained by a primary psychotic disorder (e.g., symptoms precede substance use, persist >1 month after cessation, or there is other evidence of an independent disorder). D. Does not occur exclusively during a delirium. E. Causes clinically significant distress or impairment.",
    "prevalence": "Varies by substance and setting; higher with high-potency cannabis, stimulants (amphetamines, cocaine), PCP/ketamine, and in emergency/inpatient populations.",
    "age_of_onset": "Any age depending on exposure; often late adolescence to early adulthood for substances of abuse.",
    "prognosis": "Often resolves within days to weeks of abstinence and treatment. A subset transitions to a primary psychotic disorder, especially with early heavy cannabis/stimulant exposure, family history of psychosis, or persistent symptoms beyond 1 month.",
    "neurobiology": {
      "circuitry": [
        "Mesolimbic dopaminergic overactivity driving aberrant salience and psychosis.",
        "Disruption of cortico-striato-thalamo-cortical loops affecting reality testing and arousal."
      ],
      "neurochemistry": [
        "Dopamine excess (stimulants, L-DOPA), NMDA antagonism (PCP/ketamine), serotonergic agonism (LSD/psilocybin), anticholinergic toxicity (antihistamines/anticholinergics), glucocorticoid effects (corticosteroids)."
      ],
      "genetic_environmental": "Genetic vulnerability to psychosis plus early/high-intensity exposure, polysubstance use, sleep deprivation, and psychosocial stress increase risk."
    },
    "evaluation": {
      "history_psychosocial": [
        "Chronology of use (type, dose, route), last use/withdrawal timing, prior episodes, family psychiatric history.",
        "Triggers (sleep loss, stress), access to substances, legal/social consequences."
      ],
      "medical_assessment": [
        "Vitals, full physical and neurological exam; assess for delirium.",
        "Labs as indicated: CBC, CMP, TSH, CK (if agitation/rigidity), serum/urine toxicology; pregnancy test if applicable.",
        "Consider ECG (QTc) before antipsychotics; neuroimaging if focal deficits/atypical course."
      ],
      "standardized_measures": [
        "PANSS/BPRS for severity; CIWA-Ar (alcohol withdrawal) or COWS (opioid) when relevant."
      ],
      "risk_stratification": [
        "Assess suicidality, aggression, severe agitation, dehydration, hyperthermia, rhabdomyolysis, cardiovascular risk."
      ],
      "differential_diagnosis": [
        "Primary psychotic disorders (schizophrenia, schizoaffective).",
        "Delirium (fluctuating attention, disorientation).",
        "Mood disorders with psychotic features.",
        "Psychotic disorder due to another medical condition (e.g., encephalitis, endocrine)."
      ],
      "team_and_process": "Coordinate psychiatry, addiction medicine, primary care/emergency medicine; involve family/peer supports for collateral and safety."
    },
    "symptoms": {
      "core": [
        "Persecutory or grandiose delusions",
        "Auditory, visual, or tactile hallucinations",
        "Poor insight during intoxication/withdrawal"
      ],
      "associated": [
        "Severe anxiety, agitation, insomnia",
        "Autonomic activation (stimulants), dissociation (PCP/ketamine)",
        "Mood lability, paranoia"
      ]
    },
    "severity_levels": {
      "mild": "Circumscribed psychotic symptoms with intact orientation and low safety risk.",
      "moderate": "Prominent psychosis with agitation or impaired judgment; functional disruption.",
      "severe": "Severe psychosis with danger to self/others, delirium risk, or medical instability."
    },
    "risk_factors": {
      "biological": [
        "Family history of psychosis or bipolar disorder",
        "Early-onset heavy cannabis or stimulant use",
        "Traumatic brain injury, sleep deprivation"
      ],
      "psychological": [
        "High trait paranoia or anxiety",
        "Personality vulnerability, trauma history"
      ],
      "environmental": [
        "Polysubstance use, high-potency products (e.g., concentrates)",
        "Social isolation, unstable housing"
      ]
    },
    "impact_on_life": {
      "school_work": "Absenteeism, impaired performance, disciplinary/legal issues.",
      "social": "Conflict, loss of trust, relationship breakdown.",
      "medical": "Injury, dehydration, arrhythmia, rhabdomyolysis, infections.",
      "emotional": "Fear, shame, demoralization; risk of recurrence."
    },
    "comorbidities": [
      "Substance Use Disorders (SUDs)",
      "Anxiety and depressive disorders",
      "ADHD, PTSD",
      "Medical complications of substance use"
    ],
    "treatment_approaches": {
      "psychotherapy": [
        "Motivational interviewing and contingency management for SUD.",
        "CBT for psychosis (CBTp) and relapse prevention once stabilized.",
        "Family psychoeducation; linkage to peer recovery supports."
      ],
      "medications": [
        "Antipsychotics for acute psychosis: risperidone, olanzapine, haloperidol; consider quetiapine for prominent insomnia/anxiety; clozapine is not first-line.",
        "Benzodiazepines for severe agitation or stimulant intoxication (e.g., lorazepam); avoid if significant respiratory risk.",
        "Treat withdrawal per protocols: benzodiazepines for alcohol/benzodiazepine withdrawal (CIWA-guided); alpha-2 agonists or symptomatic meds for opioid withdrawal with MOUD (buprenorphine, methadone) for OUD.",
        "Medication-assisted treatment for SUD: naltrexone/acamprosate for AUD; buprenorphine/methadone/naltrexone for OUD; consider bupropion or varenicline for nicotine.",
        "Corticosteroid- or dopaminergic-med-induced psychosis: taper/offending agent when clinically safe; use low-dose antipsychotic short term."
      ],
      "neuromodulation": [],
      "lifestyle_interventions": [
        "Strict abstinence from triggering substances; sleep restoration; hydration and nutrition.",
        "Exercise, structured daily routine, trigger/urge management."
      ],
      "care_coordination": [
        "Warm handoff to addiction services, IOP/rehab when indicated.",
        "Safety planning; consider harm-reduction education (e.g., fentanyl test strips, naloxone)."
      ]
    },
    "treatment_goals": [
      "Rapid stabilization of psychosis and safety.",
      "Achieve and maintain abstinence or reduced use via evidence-based SUD treatment.",
      "Prevent recurrence and transition to primary psychosis.",
      "Restore functioning and supports."
    ],
    "missed_diagnosis_factors": [
      "Assuming primary psychosis without establishing temporal relationship to substance use.",
      "Overlooking delirium (inattention/disorientation) as the driver of perceptual disturbances.",
      "Not recognizing medication causes (steroids, anticholinergics, dopaminergics)."
    ],
    "overdiagnosis_factors": [
      "Attributing psychosis to substances solely due to a positive tox screen without considering persistence >1 month or premorbid symptoms.",
      "Confusing intense anxiety/panic with psychosis.",
      "Mistaking culturally normative experiences for hallucinations."
    ],
    "specifiers": {
      "onset_context": [
        "With onset during intoxication",
        "With onset during withdrawal",
        "With onset after medication exposure"
      ],
      "predominant_symptom": ["With delusions", "With hallucinations"],
      "course": [
        "Single episode, in partial remission",
        "Single episode, in full remission",
        "Multiple episodes",
        "Continuous"
      ],
      "severity": ["Mild", "Moderate", "Severe"]
    },
    "warning_signs": [
      "Rapid-onset paranoia or hallucinations after use or dose change.",
      "Severe agitation, hyperthermia, or confusion.",
      "Persistent psychotic symptoms beyond expected intoxication/withdrawal window."
    ],
    "self_help_strategies": [
      "Seek urgent care during acute psychosis; do not use alone.",
      "Commit to abstinence plan; attend recovery groups; use craving-management tools.",
      "Prioritize sleep and hydration; create a relapse prevention plan (triggers, coping, contacts).",
      "Carry naloxone if opioids are involved; use harm-reduction practices."
    ],
    "developmental_stages": {
      "adolescents": [
        "Cannabis- or stimulant-related psychosis; higher progression risk to primary psychosis; emphasize family involvement and school supports."
      ],
      "adults": ["Stimulant/cannabis/PCP-related cases; occupational/legal fallout common."],
      "older_adults": [
        "Medication-induced (steroids, anticholinergics, dopaminergics); review polypharmacy and anticholinergic burden."
      ]
    },
    "real_life_examples": [
      "A 19-year-old develops persecutory delusions after daily high-potency cannabis concentrates; symptoms remit over 3 weeks with risperidone and abstinence, continues CBTp and MI to prevent relapse.",
      "A 55-year-old started on high-dose prednisone for COPD exacerbation develops visual hallucinations; tapering steroids and short-term quetiapine resolve symptoms."
    ],
    "when_to_seek_help": "Immediate evaluation for new hallucinations, delusions, severe agitation, or confusionâ€”especially after substance use, medication changes, or during withdrawal.",
    "prognosis_factors": {
      "positive_factors": [
        "Rapid abstinence and engagement in SUD treatment",
        "Short duration of psychosis and good premorbid functioning",
        "Strong family/peer supports"
      ],
      "challenging_factors": [
        "Early heavy cannabis/stimulant use",
        "Family history of psychosis",
        "Persistent symptoms >1 month after cessation",
        "Polysubstance use or homelessness"
      ]
    }
  },
  "status": "active"
}
